Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7600
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHäuser, Friederike-
dc.contributor.authorSprinzl, Martin F.-
dc.contributor.authorDreis, Kim J.-
dc.contributor.authorRenzaho, Angelique-
dc.contributor.authorYouhanen, Simon-
dc.contributor.authorKremer, Wolfgang M.-
dc.contributor.authorPodlech, Jürgen-
dc.contributor.authorGalle, Peter R.-
dc.contributor.authorLackner, Karl J.-
dc.contributor.authorRossmann, Heidi-
dc.contributor.authorLemmermann, Niels A.-
dc.date.accessioned2022-08-23T08:02:18Z-
dc.date.available2022-08-23T08:02:18Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7614-
dc.description.abstractSeveral rapid antigen tests (RATs) for the detection of SARS-CoV-2 were evaluated recently. However, reliable performance data for laboratory-based, high-throughput antigen tests are lacking. Therefore and in response to a short-term shortage of PCR reagents, we evaluated DiaSorin's LIAISON SARS-CoV-2 antigen test in comparison to RT-qPCR, and concerning the application of screening non-COVID-19 patients on hospital admission. Applying the manufacturer-recommended cut-off of 200 arbitrary units (AU/mL) the specificity of the LIAISON Test was 100%, the overall analytical sensitivity 40.2%. Lowering the cut-off to 100 AU/mL increased the sensitivity to 49.7% and decreased the specificity to 98.3%. Confining the analysis to samples with an RT-qPCR result < 25 Ct resulted in a sensitivity of 91.2%. The quality of the LIAISON test is very similar to that of good RATs described in the literature with the advantage of high throughput and the disadvantage of relatively long analysis time. It passes the WHO quality criteria for rapid antigen tests and is characterized by particularly high specificity. The LIAISON test can therefore be used for the same applications as recommended for RATs by the WHO. Due to limited sensitivity, the LIAISON test should only be used for screening, if PCR-based assays are not available.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleEvaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admissionen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7600-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleMedical microbiology and immunologyde
jgu.journal.volume210de
jgu.pages.start165de
jgu.pages.end171de
jgu.publisher.year2021-
jgu.publisher.nameSpringerde
jgu.publisher.placeBerlin u.a.de
jgu.publisher.issn1432-1831de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1007/s00430-021-00706-5de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
evaluation_of_a_laboratorybas-20220822134023960.pdf911.69 kBAdobe PDFView/Open